CERS Cerus

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...
SEC CIK
Corporate docs
IRS number
680262011
CERS stock data
()
News
COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial
3 Mar 21
Cerus Q4 EPS $(0.09), Inline, Sales $33.60M Beat $32.42M Estimate
25 Feb 21
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
25 Feb 21
Earnings Scheduled For February 25, 2021
25 Feb 21
Cerus Corporation And Shandong Zhongbaokang Medical Implements Partner To Establish Joint Venture In China To Commercialize The INTERCEPT Blood System; Cerus And Zhongbaokang To Be Sole Shareholders Of JV
24 Feb 21
Press releases
Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit
3 Mar 21
Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results
25 Feb 21
Cerus Corp. to Host Earnings Call
25 Feb 21
Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China
24 Feb 21
Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
11 Feb 21
Calendar
25 Feb 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Cerus earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.9M | 38.9M | 38.9M | 38.9M | 38.9M | 38.9M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 4.78M | 4.97M | 2.82M | 3.4M |
Cash used (since last report) | n/a | n/a | 16.52M | 17.17M | 9.74M | 11.73M |
Cash remaining | n/a | n/a | 22.38M | 21.73M | 29.16M | 27.17M |
Runway (months of cash) | n/a | n/a | 4.7 | 4.4 | 10.3 | 8.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 21 | Moore Carol | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 7,989 | 50.95K | 179,555 |
15 Mar 21 | Moore Carol | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 15,786 | 100.68K | 164,774 |
15 Mar 21 | Moore Carol | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 5,556 | 35.43K | 135,560 |
15 Mar 21 | Menard Chrystal | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 7,989 | 50.95K | 105,853 |
15 Mar 21 | Menard Chrystal | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 15,786 | 100.68K | 91,072 |
15 Mar 21 | Menard Chrystal | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 5,556 | 35.43K | 61,858 |
15 Mar 21 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 6.339 | 20,000 | 126.78K | 76,035 |
15 Mar 21 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 7,989 | 50.95K | 96,035 |
15 Mar 21 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 15,786 | 100.68K | 81,254 |
15 Mar 21 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 6.3777 | 5,556 | 35.43K | 52,040 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
84.5% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 164 |
Opened positions | 26 |
Closed positions | 22 |
Increased positions | 53 |
Reduced positions | 51 |
13F shares |
Current |
---|---|
Total value | 983.45M |
Total shares | 142.11M |
Total puts | 141.5K |
Total calls | 417.4K |
Total put/call ratio | 0.3 |
Largest owners |
Shares | Value |
---|---|---|
ARK Investment Management | 29.57M | $204.64M |
Baker Bros. Advisors | 13.71M | $94.9M |
BLK Blackrock | 12.38M | $85.66M |
CMTDF Sumitomo Mitsui Trust | 11.1M | $76.83M |
Nikko Asset Management Americas | 11.1M | $76.83M |
Primecap Management | 10.43M | $72.21M |
Vanguard | 8.68M | $60.09M |
STT State Street | 4.37M | $30.24M |
Wasatch Advisors | 2.96M | $20.49M |
Geode Capital Management | 2.67M | $18.46M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absenteeism, Aid, alienate, anesthesiologist, attacked, batch, Biden, bleeding, Cadillac, Canadian, capture, career, caution, CCPA, CEO, certified, CFO, Chair, Chinese, choice, combating, conserve, consigned, consignment, constitutionality, CPRA, cultivate, culture, defense, delete, demographic, discrimination, disparate, distancing, distrust, emotional, empowered, entrepreneurial, ergonomic, EU, extra, extracting, fact, feedback, fibrinogen, fifteen, flexible, flu, foundation, fundamentally, gap, globe, guiding, hand, hemorrhage, HHS, home, ill, imperative, Importantly, influx, innovative, insolvent, intensified, ISO, JV, lab, laying, load, Louisiana, lowest, machinery, malware, manipulation, manual, mechanism, mental, mishandling, misleading, mission, Myelodysplasia, NaN, network, nonqualified, Northern, notably, NTAP, nurse, Occasionally, online, onsite, operationally, ordinary, pandemic, percent, perseverance, persist, pharmacy, physical, PRCFC, prerequisite, prescription, presidential, professional, progressing, prophylactic, ransom, recession, recognizable, recommence, reconfigure, reconfigured, reconsider, reexamining, rejected, remote, resource, restart, resubmit, resubmitting, resumed, resumption, resurface, resurge, resurgence, rigor, SA, salary, scalable, sequester, Shield, sickle, simple, slowdown, social, speculative, spike, Stifel, stipend, strategy, strive, striving, stronger, strongly, surge, surrender, Swissmedic, temporarily, thaw, thawing, tie, tone, traditional, transmit, truthful, turnover, unexercised, unnecessary, unprecedented, urgency, vaccination, vaccine, venture, version, Virginia, week, wellbeing, Wisconsin, women, word, workflow, workforce, workplace, workstation, worsen, worsened
Removed:
absolute, accreted, adult, Aduro, automation, bargaining, Biotech, calculate, Chairman, claimed, collaborate, collective, conceived, consumed, contraction, deregulate, dilute, distributed, earning, eighteen, ending, exceeded, excise, FASB, flat, headcount, hostile, idle, imposing, inexperienced, installation, installment, jeopardize, jointly, lessee, Likewise, line, lump, Oxford, perquisite, pill, poison, practical, protocol, reclassified, reinvested, remained, reportable, Republic, resolution, seller, stated, straight, summarize, supervision, targeting, taxation, timeframe, Unaudited, unremitted, unsold, weak
Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
1 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
26 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
Current reports
8-K
Departure of Directors or Certain Officers
31 Mar 21
8-K
Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results
25 Feb 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Jan 21
8-K
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue
11 Jan 21
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
6 Jan 21
8-K
Entry into a Material Definitive Agreement
11 Dec 20
8-K
Other Events
11 Dec 20
8-K
Cerus Corporation Announces Record Third Quarter 2020 Results
29 Oct 20
8-K
Cerus Corporation Announces Record Second Quarter 2020 Results
4 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
11 Dec 20
S-3ASR
Automatic shelf registration
11 Dec 20
S-8
Registration of securities for employees
4 Aug 20
424B5
Prospectus supplement for primary offering
30 Jan 20
424B5
Prospectus supplement for primary offering
28 Jan 20
S-8
Registration of securities for employees
1 Aug 19
15-12G
Securities registration termination
5 Mar 19
424B5
Prospectus supplement for primary offering
31 Jan 18
424B5
Prospectus supplement for primary offering
29 Jan 18
424B5
Prospectus supplement for primary offering
7 Jan 18
Proxies
PRE 14A
Preliminary proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
23 May 19
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
27 Apr 18
DEFR14A
Revised proxy
30 May 17
DEF 14A
Definitive proxy
27 Apr 17
Other
SD
Conflict minerals disclosure
29 May 20
CT ORDER
Confidential treatment order
5 Feb 20
CT ORDER
Confidential treatment order
5 Feb 20
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
26 Dec 19
CT ORDER
Confidential treatment order
17 Sep 19
Ownership
4
CERUS / Vivek K Jayaraman ownership change
16 Mar 21
4
CERUS / Kevin Dennis Green ownership change
16 Mar 21
4
CERUS / William Mariner Greenman ownership change
16 Mar 21
4
CERUS / LAURENCE M CORASH ownership change
16 Mar 21
4
CERUS / Richard J Benjamin ownership change
16 Mar 21
4
CERUS / Chrystal Menard ownership change
16 Mar 21
4
CERUS / Carol Moore ownership change
16 Mar 21
4
CERUS / Carol Moore ownership change
16 Mar 21
4
CERUS / Chrystal Menard ownership change
16 Mar 21
4
CERUS / Vivek K Jayaraman ownership change
16 Mar 21
Patents
APP
Utility
System and Methods for Implementing a Biological Fluid Treatment Device
30 Dec 20
Electronic devices for treating a biological fluid and methods of operating the devices are disclosed.
APP
Utility
Biological Fluid Treatment Systems
23 Dec 20
Disclosed herein is systems, methods, and apparatuses for treating biological fluids.
APP
Utility
Systems and Methods for Implementing Treatment of Biological Fluids
23 Dec 20
Disclosed herein are systems and methods for implementing a plurality of graphical user interfaces.
GRANT
Utility
Methods for preparing platelet products
23 Nov 20
Provided herein are improved processes for preparing and treating platelet products.
GRANT
Utility
Plasma compositions and methods of use thereof
12 Oct 20
Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.
Transcripts
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
20 Feb 20
2019 Q3
Earnings call transcript
30 Oct 19
2019 Q2
Earnings call transcript
1 Aug 19
2019 Q1
Earnings call transcript
7 May 19
2018 Q4
Earnings call transcript
26 Feb 19
2018 Q3
Earnings call transcript
1 Nov 18
Reddit threads
ARK Invest 03/22 Stock position change
23 Mar 21
Daily Discussion Thread - February 25th, 2021
25 Feb 21
Daily Discussion Thread - February 24th, 2021
24 Feb 21
Daily Discussion Thread - February 23rd, 2021
23 Feb 21
Daily Discussion Thread - October 29th, 2020
29 Oct 20
Daily Discussion Thread - October 28th, 2020
28 Oct 20